Research Analysts Issue Forecasts for Clene Q1 Earnings

Clene Inc. (NASDAQ:CLNN) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Clene in a note issued to investors on Monday, March 24th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($1.11) for the quarter. HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.28) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($3.02) EPS and FY2027 earnings at $0.52 EPS.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Monday, March 24th. The company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.13 million. Clene had a negative return on equity of 1,106.30% and a negative net margin of 8,556.77%.

Separately, D. Boral Capital reiterated a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Monday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Clene has a consensus rating of “Buy” and an average target price of $55.25.

Clene Price Performance

CLNN opened at $3.54 on Wednesday. The company has a market capitalization of $29.47 million, a price-to-earnings ratio of -0.67 and a beta of 0.27. The business’s 50-day moving average price is $4.49 and its two-hundred day moving average price is $4.88. Clene has a 1 year low of $3.37 and a 1 year high of $9.20.

Institutional Investors Weigh In On Clene

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fullcircle Wealth LLC acquired a new stake in shares of Clene in the fourth quarter valued at about $69,000. Renaissance Technologies LLC bought a new position in Clene in the fourth quarter valued at approximately $96,000. Geode Capital Management LLC increased its position in shares of Clene by 52.9% during the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after purchasing an additional 22,539 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Clene during the 4th quarter worth approximately $69,000. Finally, Parsons Capital Management Inc. RI bought a new stake in shares of Clene during the 4th quarter worth approximately $194,000. 23.28% of the stock is owned by institutional investors.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.